qookgame.com콘돔구매 | 콘돔구매 | 슬림제로001슬림제로001 | 슬림제로0010.1콘돔 | 슬림제로001콘돔싸게 …
페이지 정보
작성자 츠쇼븨허42 작성일20-04-09 03:23 조회77회 댓글0건본문
PS2 Longplay [019] God of War 作成者: Project Longplay 1 年前 7 時間 53 分 1,160,163 回視?
LOS ANGELES--( / ) April 30, 2019 -- Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today results from its landmark prospective, multi-center, pivotal clinical trial to validate the EyeArt® AI Eye Screening System for autonomous detection of diabetic retinopathy (DR), a blinding disease estimated to affect 191 million people globally by the year 2030[1]. The results were presented at the ARVO Imaging in the Eye Conference by Jennifer Lim, MD, Marion H. Schenk Esq. Chair and Professor of Ophthalmology and Director of Retina Service at the University of Illinois at Chicago.
The EyeArt AI Eye Screening System makes in-clinic, real-time DR screening possible for any physician, enabling quick and accurate identification of patients with referable DR during diabetic patient’s regular physician visit. Once the patient’s fundus images have been captured and submitted to the EyeArt System, the DR screening results are available to view and export to a PDF report in less than 60 seconds. The EyeArt system can free eye care specialists to focus on sight-saving treatment rather than screening for DR.
Key aspects of this prospective, multi-center, pivotal clinical trial (NCT03112005) include:
· 942 subjects enrolled at 15 centers that included primary care, endocrinology, ophthalmology, and retina specialty clinics.
· EyeArt AI system’s assessment of 2-field undilated images was compared to comprehensive clinical reference standard comprising adjudicated grading of 4 wide-field dilated stereo images on the ETDRS severity scale[2]. The grading was performed by the Wisconsin Fundus Photograph Reading Center.
· Multiple fundus camera models were included and evaluated with the EyeArt AI eye screening system.
· Board-certified ophthalmologists (in a subset of sites) independently performed dilated ophthalmoscopy, the most-prevalent method for DR screening today.
Study results show that all pre-determined primary endpoints were met with p<0.0001. Topline results from the pivotal study are in the table below (details here ):
(To view the table, please visit )
“This study is significant as it shows this AI system is quite accurate in determining the presence of referable diabetic retinopathy by a very rigorous method which compared the AI results to that of photos read by expert graders of diabetic retinopathy,” said Dr. Jennifer Lim, an Investigator in the EyeArt pivotal trial. “In this prospective multi-center study, we showed feasibility and applicability of this system for screening for referable diabetic retinopathy. This holds great promise in accomplishing screening of the millions of diabetic patients for referable diabetic retinopathy in order to identify those at risk of visual loss and refer them for prompt treatment by ophthalmologists!” Dr. Lim continued, “The high sensitivity and specificity achieved by the EyeArt system shows that it can enable point-of-care DR screening and that it is a safe way to identify patients with DR who require ophthalmology referrals.”
“Completion of this EyeArt prospective pivotal trial is an exciting step for Eyenuk, and this study once again validates the EyeArt System’s exceptional diagnostic sensitivity and specificity without needing dilation,” said Kaushal Solanki, PhD, Founder and CEO of Eyenuk. “Today I am proud to say that artificial intelligence is living up to its promise and can deliver substantial and meaningful impact to patients’ lives globally. Regular and quality eye screening can soon be accessible and affordable to hundreds of millions of people living with diabetes, leading to vision preservation for many of them.”
Eyenuk will showcase its EyeArt AI Eye Screening System at Booth #1637 in the ARVO Exhibition Hall at the Vancouver Convention Centre.
About the EyeArt® AI Eye Screening System
The EyeArt AI Eye Screening System is the most extensively validated AI technology for autonomous detection of DR, tested in the real-world on more than half million patient visits globally with over two million images collected in real-world clinical environments. The EyeArt System was developed with funding from the US National Institutes of Health (NIH) and is validated by the UK National Health Service (NHS). The EyeArt System has CE marking in the EU and a Health Canada license. In the US, the EyeArt System is limited by federal law to investigational use.
VIDEO: Learn more about the EyeArt AI Eye Screening System for Diabetic Retinopathy
About Diabetic Retinopathy (DR)
DR is a complication of diabetes caused by damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina). It is a silently progressing disease that at first may cause no symptoms or only mild vision problems. Eventually, it can cause blindness. The condition can develop in anyone who has type 1 or type 2 diabetes.[3] It is estimated that one-third of all patients with diabetes will develop DR,[4] making it the leading cause of vision loss in working-age adults.[5]
While DR screening is recommended for all diabetic patients, less than half get screened annually[1], even in the developed world. Since diabetic patients outnumber ophthalmologists by 1,600 to 1 in the U.S.,[6] there are just not enough eye care specialists to meet the DR screening needs of the growing diabetic population. Even for those receiving their annual screening, ophthalmology appointment wait times for DR screening can be weeks or even months.
About Eyenuk, Inc.
Eyenuk, Inc. is a global artificial intelligence (AI) medical technology and services company and the leader in real-world AI Eye Screening™ for autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and disease surveillance. Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk and Alzheimer’s disease.
EyeArt is a registered trademark of Eyenuk, Inc.
[1] International Diabetes Federation. IDF Diabetes atlas, Sixth edition, Brussels, Belgium. 2015.
[2] Early Treatment Diabetic Retinopathy Study Research Group Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. 1991, Ophthalmology 98(5 Suppl):823-833.
[3]
[4] Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556-64. doi: 10.2337/dc11-1909
[5] Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Research. 2012;47:171-188. doi: 10.1159/000329603
[6] and
View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
SAN FRANCISCO--( / ) May 30, 2019 -- Binance, the world’s largest cryptocurrency exchange by trading volume and developer of proprietary blockchain Binance Chain, and Cred, the leading platform for 굿타임콘돔 crypto lending and borrowing, today announced an agreement to work together to spur the decentralization of finance. As part of the agreement, Cred will migrate a portion 스포츠토토365 SANits ERC20 LBA tokens to Binance Chain and will become the official lending and borrowing platform for the DeFi ecosystem. As both an investor 토토365꽁머니 SANpartner in Cred, Binance will also look for opportunities to leverage and support Cred’s industry-leading services within the Binance ecosystem.
“We are delighted to be working with Cred to help scale their efforts 토토365주소 “Wemore markets and 토토365카지노 “Wearound the world 굿타임콘돔 through the power of the Binance Chain, which has a one-second block 굿타임콘돔 time and will ensure transactions and interactions by 굿타임콘돔 Cred’s users will be fast, efficient and effortless,” said Ted Lin, Chief Growth Officer of Binance.
Cred is a licensed lender, based in 굿타임콘돔 California and has secured over $300 million in lending capital. Cred enables crypto wallet providers, custodians, exchanges 토토365양귀비 Credcrypto application providers the ability to offer some of the most competitive lending and borrowing rates in the industry. This year, Cred has announced partnerships with several influential organizations and custodians in the crypto community. Cred LBA holders will be able to commit their crypto 도박365 Creda fixed term and have the option to rollover assets for additional periods. Customers receive the best rates when staking Cred’s 토토꽁머니 Credtoken. No account minimum is needed and interest is paid out in Stablecoin. The principal is paid back in the crypto amounts that were initially received.
“Binance has been 토토웹 “Binancestrong 토토일보 “Binanceand investor from Cred’s inception and we are very 굿타임콘돔 happy to support Binance Chain and continue to collaborate with Binance to bring decentralized finance to 토토꽁머니환전가능 “Binancein a sustainable way,” said Dan Schatt, Co-Founder of Cred. “We look forward to continuing the Cred-Binance partnership.”
Cred is backed by 토토꽁머니환전사이트 Credof the largest investors in crypto and tech including Binance Labs, 500 Startups, Arrington XRP Capital, 굿타임콘돔 Blocktower and FBG Capital. Cred is also a founding member of the Universal Protocol Alliance, a board member of the Blockchain 굿타임콘돔 Advocacy 굿타임콘돔 Coalition.
About 굿타임콘돔 토토꽁머니50000 About
Cred is a decentralized global lending platform 꽁머니홍보방 Cred굿타임콘돔 facilitates open access to credit anywhere 굿타임콘돔 and anytime. Founded by former PayPal financial technology veterans, Cred has secured over $300 million of lending capital with offices in San Francisco and Shanghai. Cred’s mission is to harness the 굿타임콘돔 power of blockchain to allow everyone to benefit from low-cost credit products. Cred brings together a diverse team of entrepreneurial leaders, machine learning, and the power of blockchain technology. 가입시꽁머니사이트 Credmore information, visit mycred.io or follow us on Twitter, LinkedIn, or join our community on Telegram.
환전가능꽁머니 About 굿타임콘돔 가입꽁머니환전 About
Binance is a blockchain ecosystem comprised of several arms to serve the greater mission of blockchain advancement and the freedom of money. The Binance ecosystem is comprised of Binance Exchange (the 굿타임콘돔 leading global cryptocurrency exchange), Labs (venture capital arm and incubator), Launchpad (token sale platform), Academy (educational portal), Research (market analysis), Charity Foundation (blockchain-powered donation platform and non-profit for aiding in sustainability) and Trust 승인전화없는꽁머니사이트 Binance(Binance’s official multi-coin wallet and dApps browser), as well 굿타임콘돔 as Binance Chain, a blockchain software system developed by Binance and the community.
To 꽁머니환전가능사이트 To 굿타임콘돔 more visit:
View source version on businesswire.com:Korea Newswire distributes your news across every 꽁머니그래프 Viewchannels 굿타임콘돔 through the industry’s largest press release 야구분석자료 Viewnetwork
댓글목록
등록된 댓글이 없습니다.